Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-direct...
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016—of which 490 000 were multidrug resistant (MDR), with less than 50% survival after receiving recommended treatment regimens. Concerted ef...
Alternative Titles
Full title
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2019046534
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2019046534
Other Identifiers
ISSN
1473-3099,1474-4457
E-ISSN
1474-4457
DOI
10.1016/S1473-3099(18)30110-5
